• 1
    Logroscino G, Traynor BJ, Hardiman O et al. Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatry 2010; 81: 385390.
  • 2
    Wijesekera LC, Leigh PN. Amyotrophic lateral sclerosis. Orphanet J Rare Dis 2009; 4: 325.
  • 3
    Kiernan MC, Vucic S, Cheah BC et al. Amyotrophic lateral sclerosis. Lancet 2011; 377: 942955.
  • 4
    Talbot K. Motor neuron disease: The bare essentials. Pract Neurol 2009; 9: 303309.
  • 5
    Piao YS, Wakabayashi K, Kakita A et al. Neuropathology with clinical correlations of sporadic amyotrophic lateral sclerosis: 102 autopsy cases examined between 1962 and 2000. Brain Pathol 2003; 13: 1022.
  • 6
    Neumann M, Sampathu DM, Kwong LK et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006; 314: 130133.
  • 7
    Pastula DM, Moore DH, Bedlack RS. Creatine for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev 2010; 6: CD005225.
  • 8
    Aggarwal S, Cudkowicz M. ALS drug development: Reflections from the past and a way forward. Neurotherapeutics 2008; 5: 516527.
  • 9
    Zoccolella S, Santamato A, Lamberti P. Current and emerging treatments for amyotrophic lateral sclerosis. Neuropsychiatr Dis Treat 2009; 5: 577595.
  • 10
    Miller RG, Mitchell JD, Lyon M et al. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2007; 1: CD001447.
  • 11
    Mazzini L, Ferrero I, Luparello V et al. Mesenchymal stem cell transplantation in amyotrophic lateral sclerosis: A Phase I clinical trial. Exp Neurol 2010; 223: 229237.
  • 12
    Mazzini L, Fagioli F, Boccaletti R et al. Stem cell therapy in amyotrophic lateral sclerosis: A methodological approach in humans. Amyotroph Lateral Scler Other Motor Neuron Disord 2003; 4: 158161.
  • 13
    Deda H, Inci MC, Kurekci AE et al. Treatment of amyotrophic lateral sclerosis patients by autologous bone marrow-derived hematopoietic stem cell transplantation: A 1-year follow-up. Cytotherapy 2009; 11: 1825.
  • 14
    Martinez HR, Gonzalez-Garza MT, Moreno-Cuevas JE et al. Stem-cell transplantation into the frontal motor cortex in amyotrophic lateral sclerosis patients. Cytotherapy 2009; 11: 2634.
  • 15
    Blot S, Poirier C, Dreyfus PA. The mouse mutation muscle deficient (mdf) is characterized by a progressive motoneuron disease. J Neuropathol Exp Neurol 1995; 54: 812825.
  • 16
    Cabanes C, Bonilla S, Tabares L et al. Neuroprotective effect of adult hematopoietic stem cells in a mouse model of motoneuron degeneration. Neurobiol Dis 2007; 26: 408418.
  • 17
    Moraleda JM, Blanquer M, Bleda P et al. Adult stem cell therapy: Dream or reality? Transpl Immunol 2006; 17: 7477.
  • 18
    Ioannidis JP, Evans SJ, Gotzsche PC et al. Better reporting of harms in randomized trials: An extension of the CONSORT statement. Ann Intern Med 2004; 141: 781788.
  • 19
    De Troyer A, Kirkwood PA, Wilson TA. Respiratory action of the intercostal muscles. Physiol Rev 2005; 85: 717756.
  • 20
    Trotti A, Colevas AD, Setser A et al. CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003; 13: 176181.
  • 21
    Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial “Clinical limits of amyotrophic lateral sclerosis” workshop contributors. J Neurol Sci 1994; 124( suppl): 96107.
  • 22
    Brooks BR, Miller RG, Swash M et al. El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1: 293299.
  • 23
    Blanquer M, Perez-Espejo MA, Martinez-Lage JF et al. A surgical technique of spinal cord cell transplantation in amyotrophic lateral sclerosis. J Neurosci Methods 2010; 191: 255257.
  • 24
    Polkey MI, Green M, Moxham J. Measurement of respiratory muscle strength. Thorax 1995; 50: 11311135.
  • 25
    Cruccu G, Aminoff MJ, Curio G et al. Recommendations for the clinical use of somatosensory-evoked potentials. Clin Neurophysiol 2008; 119: 17051719.
  • 26
    Iber C, Ancoli-Israel S, Cheeson A et al. The AASM Manual for the Scoring of Sleep and Associated Events-Rules, Terminology and Technical Specifications. Westchester, IL: American Academy of Sleep Medicine, 2007.
  • 27
    Mackenzie IR, Bigio EH, Ince PG et al. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol 2007; 61: 427434.
  • 28
    Mackenzie IR, Rademakers R, Neumann M. TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol 2010; 9: 9951007.
  • 29
    Suzuki M, Svendsen CN. Combining growth factor and stem cell therapy for amyotrophic lateral sclerosis. Trends Neurosci 2008; 31: 192198.
  • 30
    Pastor D, Viso-León M, Jones J et al. Comparative effects between bone marrow and mesenchymal stem cell transplantation in GDNF expression and motor function recovery in a motorneuron degenerative mouse model. Stem Cell Rev 2011; [Epub ahead of print].
  • 31
    Blanquer M, Perez Espejo MA, Iniesta F et al. [Bone marrow stem cell transplantation in amyotrophic lateral sclerosis: Technical aspects and preliminary results from a clinical trial]. Methods Find Exp Clin Pharmacol 2010; 32( suppl A): 3137.